DRAWINGS




Figure 1



a
Hep3B
Solvent
M1
ns
P < 0.001
i.t.
Tumor volume (cm³)
Body weight (g)
Days after tumor inoculation
b
LoVo
c
Hep3B
i.v.
d
Hep3B
Relative virus RNA quantity
Days after administration
Tumor
Brain
Heart
Kidney
Liver
Lung
Muscle
Spleen

Figure 2



a
Relative mRNA expression (×10⁻³)
L-02
PLC
HCT 116
HEB
SCaBER
T24
Hep3B
LoVo
ND
b
ZAP
β-actin
c
L-02 Hep G2
ZAP
β-actin
Relative cell viability (%)
Normalized ZAP expression
**
d
L-02
PLC
HCT116
Relative cell viability (%)
siNC
siZAP
MOI
ns
e
Relative virus titer
f
Relative virus RNA
g
L-02
HCT116
PLC
siNC
siZAP
ZAP
NS3
E1
GAPDH
h
Hep3B
Relative cell viatiliby (%)
GFP
ZAP
MOI
i
Relative virus titer
j
Relative virus RNA
k
Hep3B
Vector
GFP
ZAP
NS3
E1
β-actin

Figure 3



*
Normalized ZAP expression
3.0
2.5
2.0
1.5
1.0
0.5
0.0
inhibition rate
≦10%
>10%

Figure 4



a
case 1
case 2
case 3
N
T
b
Normalized ZAP expression
50
40
30
20
10
0
***
***
***
N
T
N
T
N
T
Liver
Colorectum
Bladder
c
Percentage
100
80
60
40
20
0
Liver
Colorectum
Bladder
(n=247)
(n=152)
(n=107)
low expression of ZAP in tumor

Figure 5

SEQUENCE LISTING

<160> 9

<170> PatentIn version 3.5

<210> 1
<211> 20
<212> DNA
<213> synthetic sequence

<400> 1
gatcattgct cctcctgagc 20

<210> 2
<211> 20
<212> DNA
<213> synthetic sequence

<400> 2
actcctgctt gctgatccac 20

<210> 3
<211> 21
<212> DNA
<213> synthetic sequence

<400> 3
gttccaacag gcgtcaccat c 21

<210> 4
<211> 24
<212> DNA
<213> synthetic sequence

<400> 4
acacattctt gtctagcaca gtcc 24

<210> 5
<211> 21
<212> DNA
<213> synthetic sequence

<400> 5
tcacgaactc tctggactga a 21

<210> 6
<211> 23
<212> DNA
<213> synthetic sequence

<400> 6
acttttgcat atctcgggca taa 23

<210> 7
<211> 19
<212> DNA
<213> synthetic sequence

<400> 7

ccaagagtag cacttgtta 19

<210> 8
<211> 21
<212> DNA/RNA
<213> synthetic sequence

<400> 8
ccaagaguag cacuuguuat t 21

<210> 9
<211> 21
<212> DNA/RNA
<213> synthetic sequence

<400> 9
uaacaagugc uacucuuggt t 21